News

In the News

In partnership with our network partners, together, we have shared research on real-world treatment patterns in breast and non-small cell lung cancer.

Hero News

10/15/2021

The 25 small and midsize companies that offer the best perks and benefits

By Chris Burkhardt

Comparably just released its latest ranking: the Best Companies for Perks and Benefits.

Read

10/11/2021

Taking the Call: Multisource Datasets Speed Real-World Data Fitness Assessments in Oncology

By Chris Burkhardt

An article published by Desai, et al1 that appeared in the May/June 2021 issue of Values & Outcomes Spotlight defined the promise and challenges associated with using real-world evidence (RWE) that draws on real-world data (RWD) sources for health economics and outcomes research (HEOR).

Read

10/06/2021

Syapse, Merck Collaborate on Cancer Research Fueled by Real-World Data

By Chris Burkhardt

The drugmaker will use Syapse’s real-world clinical, molecular, treatment, and outcomes data on cancer patients to advance research and improve care.

Read

Load more

Press Releases

12/06/2021

Syapse Announces New Studies Published at Virtual ISPOR Europe 2021

By Chris Burkhardt

San Francisco, CA – December 6, 2021 – Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, presented five abstracts at Virtual ISPOR Europe 2021, the leading global conference for health economics and outcomes research (HEOR), held last week.

Read

10/13/2021

Syapse Senior People Manager Recognized as 2021 WellBeyond Leader of the Year for Emerging Companies While the Company Takes Home Three Comparably Awards

By Antoinette Cummins

Syapse has been recognized as a Best Company for Happiness, Work-Life Balance, and Perks and Benefits by the 2021 Comparably Awards. This recognition comes on the heels of Syapse’s Senior Manager of People Operations, Mehwish Rana, being honored as the WellBeyond Leader of the Year for Emerging Companies by the Sequoia 2021 WellBeyond Awards.

Read

10/06/2021

Syapse Enters Real-World Data Collaboration with Merck to Inform and Improve Cancer Care

By Chris Burkhardt

San Francisco, CA – October 6, 2021 – Syapse®, a leading real-word evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real world care, today announced that it has entered into a research collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will leverage real-world data (RWD) to drive high-quality insights that will impact patient care and advance oncology research.

Read

Load more

Events

Webinar

2021 Syapse Precision Medicine Council: Keynote Sessions

December 07, 2021

Every year, Syapse hosts leaders in real-world evidence and precision medicine across the Syapse Learning Health Network of health system, life science, and regulatory partners and has historically been an invite-only meeting for members of the Syapse Learning Health Network. This year, we are expanding the keynote sessions to any health system, life science, lab, or regulator interested in attending! You can also reach out to events@syapse.com if you are interested in learning more about the full meeting.

Conference

Syapse x HLTH 2021: Join us!

December 07, 2021

Meet us at HLTH 2021! Visit our kiosk (K-548) to learn how the Syapse Insight Analytics Platform can transform your disparate, fragmented real-world data into actionable insights. We recommend booking a 15-minute meeting with a member of our team (see event link below)! On Monday, October 18 at 6:40pm EST we will be hosting a 10-minute Tech Talk in Hall A. Divya Harjani, SD of Business Development at Syapse will walk through key considerations for evaluating your RWE, and how high quality RWD is the cornerstone of RWE you can trust.

Webinar

Leveraging RWE to Empower a Health System's Oncology Precision Medicine Program

September 15, 2021

Two of three leading health system executives place investment in precision medicine as a strategic priority, according to a recent study by the Health Management Academy. Prior to the COVID-19 pandemic, the broader industry — life sciences, commercial labs, and the FDA — was accelerating development and approval of new testing technologies and targeted therapies. The pandemic further demonstrated the promise and the challenges of precision sequencing and necessitated urgent innovations in trial design and real-world evidence. In this webinar, leaders from Advocate Aurora Health will distill best practices from their Oncology Precision Medicine program and discuss the role of real-world data in driving impact on patient care.

Let's chat.

If you’d like to learn more about Syapse, tell us a little about yourself and we will reach out as soon as possible.